Last reviewed · How we verify

NCT07499050

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Recruiting now Phase 1 Last updated 13 April 2026
What this trial tests

Phase 1 trial testing RO7795081 in Healthy Volunteers in 30 participants. Currently enrolling.

Timeline
30 March 2026
Primary endpoint
29 December 2026
29 December 2026

Quick facts

Lead sponsorHoffmann-La Roche
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Enrollment30
Start date30 March 2026
Primary completion29 December 2026
Estimated completion29 December 2026
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteers or Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of RO7795081

Trials testing the same drug.

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Hoffmann-La Roche trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07499050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing